Figure 2From: Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trialsCombined results according to sensitivity analysis - Primary outcomes. CI: confidence interval; PFS: progression free survival; OS: overall survival; BEVA: bevacizumab.Back to article page